Mnexspike Injection, Suspension
Product Images NDC 80777-400

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Mnexspike (NDC 80777-400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Moderna Us, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mnexspike (covid-19 Vaccine, Mrna) 2025-2026 Formula Injectable Suspension For Intramuscular Use Single-dose Pre-filled Syringe 0.2 mL (Image 01)

The image shows a packaging label for mNEXSPIKE, a COVID-19 Vaccine, mRNA, 0.2 mL single dose injection suspension for intramuscular use. It includes the product NDC 80777-400-17 and notes it is for prescription use. The label indicates the 2025-2026 formula and is manufactured for Moderna US, Inc. The label also has spaces for lot and expiration information and features a pull tab and barcode.*

FDA Label Image

Mnexspike (covid-19 Vaccine, Mrna) 2025-2026 Formula Injectable Suspension For Intramuscular Use Single-dose Pre-filled Syringe Carton 0.2 mL (80777-400-60) (Image 02)

Packaging label for mNEXSPIKE COVID-19 Vaccine, mRNA, 10 micrograms per 0.2 mL injectable suspension for intramuscular use, manufactured by Moderna US, Inc. The box contains 10 single-dose pre-filled syringes. The label specifies the 2025-2026 formula and indicates use for individuals 65 years and older, as well as 12 through 64 years at high risk for severe COVID-19.*

FDA Label Image

Mnexspike (covid-19 Vaccine, Mrna) 2025-2026 Formula Injectable Suspension For Intramuscular Use Single-dose Pre-filled Syringe Carton 0.2 mL (80777-400-61) (Image 03)

mNEXSPIKE COVID-19 Vaccine, mRNA 10 ug/.2 mL injection suspension packaging label for intramuscular use. The label states it is the 2025-2026 formula, intended for ages 65 and older, and for ages 12 through 64 at high risk of severe COVID-19. The package contains 2 single-dose pre-filled syringes, each 0.2 mL. Labeler is Moderna US, Inc. The design includes text details, barcodes, and the Moderna logo.*

FDA Label Image

Mnexspike (covid-19 Vaccine, Mrna) 2025-2026 Formula Injectable Suspension For Intramuscular Use Single-dose Pre-filled Syringe Carton 0.2 mL (80777-400-62) (Image 04)

mNEXSPIKE COVID-19 Vaccine, mRNA 10 ug/0.2 mL injectable suspension for intramuscular use. The packaging indicates it is a single-dose pre-filled syringe labeled for individuals 65 years and older, and those aged 12 through 64 at high risk for severe COVID-19. The manufacturer is Moderna US, Inc., with NDC 80777-400. The label notes the 2025-2026 formula and states no preservatives and no natural rubber latex content.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.